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ABSTRACT
Background    Tocotrienols, members of the vitamin E 
family, exist in four different isoforms (a, b, g and d to-
cotrienol) that have can be protective against brain dam-
age, as well as having anticancer effects in vivo and in 
vitro. We have shown that g-tocotrienol inhibits human 
airway smooth muscle cell proliferation and migration 
induced by platelet-derived growth factor (PDGF)-BB 
by suppressing RhoA activation. In this study, we tested 
whether g-tocotrienol modulates transforming growth 
factor (TGF) -b-induced induction of human airway 
smooth muscle (ASM) into a contractile phenotype and 
concomitant synthesis of extracellular matrix proteins. 
Methods    ASM cells were stimulated with TGF-b1 (2 
ng/mL) for 48 hours and the effect of g-tocotrienol (50 
μM) on a-smooth muscle actin, fibronectin and colla-
gen I expression was assessed using Western blotting. 
The signaling pathways involved in TGF-b1 stimulation 
were also investigated. 
Results    TGF-b1 increased a-smooth muscle actin, fi-
bronectin and collagen Ⅰ abundance by 3- to 5-fold. This 
response was inhibited significantly by g-tocotrienol. 
Furthermore, g-tocotrienol suppressed RhoA activation, 
but did not affect Smad2 or Smad3 phosphorylation. 
Conclusion    These results indicate that g-tocotrienol 
has potential for benefit in modulating on airway re-
modeling in asthma, likely via a mechanism involving 
the suppression of TGF-β activation of RhoA.
Key words    airway smooth muscle; asthma; g-Tocotrie-
nol; remodeling; vitamin E
Airway wall remodeling is one of the characteristic 
features of asthma. The structural changes in airway 
remodeling include epithelial cell shedding, basement 
membrane thickening, submucosal fibrosis and myofi-
broblast accumulation, airway smooth muscle (ASM) 
cell hyperplasia and hypertrophy, and adventitial fibro-
sis.1 Several inflammatory mediators play important 
roles in airway remodeling,2, 3 and among these, trans-
forming growth factor b1 (TGF-b) plays a predominant 
role through its capacity to induce extracellular matrix 
protein synthesis and profibrotic differentiation of ASM 
cells.4–6 TGF-β1 binds to its dimeric serine/threonine 
kinase receptor which facilitates phosphorylation of 
Smad2 and Smad3 to initiate a canonical signaling 
cascade.7 Sagara et al. have confirmed an association of 
TGF-b1/Smad2 signaling with subsequent airway re-
modeling in asthma.8 
 Current asthma therapies, such as inhaled cortico-
steroid, b2 agonists, muscarinic receptor antagonists 
and leukotriene receptor antagonists, have limited ef-
fects on airway remodeling.9 Bronchial thermoplasty is 
a nonpharmacological procedure that targets ASM bun-
dles.10, 11 However, a recent study showed that the effects 
of bronchial thermoplasty on bronchial wall thickening 
may be transient.12
 Vitamin E exhibits antioxidant activity and has 
been evaluated for its effect in asthma since oxidative 
stress is related to the pathogenesis of inflammatory air-
way disease.13 Nonetheless, the therapeutic efficacy of 
vitamin E in asthma remains equivocal.14, 15
 In nature, vitamin E exists in eight different iso-
forms; a, b, g, and d tocopherols and tocotrienols. The 
major component of vitamin E is a-tocopherol, whereas 
tocotrienols are less abundant. Beyond their antioxidant 
capabilities, tocotrienols also have pharmacological ef-
fects on various cell types. Tocotrienol has been shown 
to inhibit proliferation of breast, prostate, and lung 
cancer cell lines.16 Yap et al. reported that g-tocotrienol 
inhibits proliferation of a breast cancer cell line through 
downregulation of inhibitor of differentiation 1 (Id1),17 
which has been reported to be crucial for differentiation 
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of fibroblasts.18, 19
 RhoA signaling is an important regulator of airway 
remodeling in asthma since activation of the RhoA/
Rho kinase pathway is related to airway smooth mus-
cle contraction, proliferation and cell migration.20 We 
have reported that g-tocotrienol inhibits proliferation 
and migration of ASM cells through inhibition of RhoA 
activation.21 Schaafsma et al reported that the synthesis 
and secretion of extracellular matrix protein is mediated 
through RhoA activation in ASM cells.22 Therefore, we 
considered that g-tocotrienol could inhibit ASM cellular 
differentiation and synthesis of extracellular matrix pro-
tein.
 In this study, we investigated if and how g-tocot-
rienol inhibits TGF-b1 induction of a hypertrophic, 
contractile phenotype in human ASM cells, as well as 
assessing its impact on TGF-β1-induced biosynthesis of 
extracellular matrix proteins. 
MATERIALS AND METHODS
Human ASM cells and culture conditions
ASM cells immortalized by stable expression of human 
telomerase reverse transcriptase (hTERT) were a kind 
gift from Dr. Andrew J. Halayko at the University of 
Manitoba. Cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS), 100 mg/mL penicillin, and 100 mg/mL 
streptomycin at 37 °C in a humidified 5% CO2 atmo-
sphere. All experiments were performed in minimum of 
three different cell lines.
Stimulation of ASM cells with TGF-β1
ASM cells were seeded in a 60 mm dish and allowed to 
grow to confluence. The cells were then serum starved 
for 24 h and incubated with 10 to 50 mM g-tocotrienol 
for 1 h, followed by stimulation with 2 ng/mL TGF-b1 
for the intended duration.
Immunocytochemical analysis 
ASM cells were seeded on coverslips and allowed to 
grow to confluence. The cells were then serum starved 
for 24 h and stimulated with TGF-b1 in the presence or 
absence of 50 mM g-tocotrienol for 48 h. The cells were 
washed with CB buffer [10 mM 2-(4-Morpholino) eth-
anesulfonic acid, 150 mM NaCl, 5 mM glucose, and 5 
mM MgCl2] and fixed with 3% paraformaldehyde and 
3% triton-X for 5 min. After washing with CB buffer, 
the coverslips were incubated with 5% bovine serum 
albumin (BSA) for 1 h, and then mouse anti-a-smooth 
muscle actin antibody (1:100; Sigma, St Louis, Mo) 
was added to the coverslips and incubated overnight at 
4 °C in a humidified chamber. After washing with cy-
to-Tris buffered saline (TBS) with 0.1% Tween 20, the 
coverslips were incubated with Alexa Fluor 568 conju-
gated goat anti-mouse IgG antibody (1:50; Molecular 
Probes, Eugene, OR) for 1 h at room temperature. The 
nuclei were then stained with 300 nM 4’, 6-diamidi-
no-2-phenylindole (DAPI) (Molecular Probes) for 2 min. 
The coverslips were mounted onto slides with anti-fade 
(Molecular Probes) and evaluated using fluorescence 
microscopy (Olympus, Tokyo, Japan).
Preparation of cell lysates and Western blotting
Cells were washed with ice-cold phosphate buffered 
saline (PBS) and lysed in radioimmunoprecipitation as-
say buffer (RIPA) (50 mM Tris HCl, pH 7.4; 1% NP-40; 
0.25% sodium deoxycholate; 150 mM NaCl; 1 mM Eth-
ylenediaminetetraacetic acid (EDTA), 1 mM Na3VO4, 
1 mM NaF, and protease inhibitors). Equal amounts of 
protein were separated by electrophoresis and trans-
ferred to polyvinylidene difluoride (PVDF) membranes 
(GE Healthcare Lifescience, Buckinghamshire, UK). 
After blocking with 5% milk in TBS (20 mM Tris, 150 
mM NaCl, pH 7.6) containing 0.1% Tween 20 (TBS-T) 
for 1 h at room temperature, blots were incubated over-
night at 4 °C with 0.1% TBS-T containing monoclonal 
anti-a-smooth muscle actin antibody (1:2000; Sigma), 
monoclonal anti-b-actin antibody (1:10000; Cell Sig-
naling Technology, Danvers, MA), monoclonal anti-fi-
bronectin antibody (1:1000; Santa Cruz Biotechnology, 
Santa Cruz, CA), polyclonal anti-collagen1A2 antibody 
(1:1000; Cell Signaling Technology), monoclonal an-
ti-Smad2 antibody (1:1000; Cell Signaling Technology), 
polyclonal anti-phospho-Smad2, anti-phospho Smad3, 
and anti-Smad3 antibody (1:1000; Cell Signaling Tech-
nology), monoclonal anti-Id1 antibody (1:200; Cell 
Signaling Technology) were used. After incubation 
with the primary antibodies, membranes were washed 
and incubated with horseradish peroxidase-conjugated 
anti-rabbit IgG (1:5000; GE Healthcare Lifescience) or 
anti-mouse IgG (1:3000; GE Healthcare Lifescience) 
for 1 h at room temperature. Immunoreactive species 
were visualized on an ImageQuant LAS 4000 mini (GE 
Healthcare Lifescience) with ECL reagents (GE Health-
care Lifescience) and bands were quantified by densi-
tometry using TotalLab Quant software (Newcastle, 
UK). 
RhoA activation assay
RhoA activity was measured using an Active Rho de-
tection kit (Cell Signaling Technology, Danvers, MA) 
according to the manufacturer’s protocol. Samples were 
separated by electrophoresis and transferred to PVDF 
membranes (GE Healthcare Lifescience). After blocking 
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Fig. 1. g-Tocotrienol inhibits the TGF-b1-in-
duced expression of a-smooth muscle actin. 
hTERT-ASM cells were pretreated with 
g-tocotrienol for 1 h and then stimulated with 
TGF-b1 (2 ng/mL) for 48 h. Western blotting 
analysis showed that relative abundance of 
a-SMA was increased by TGF-b1 and g-tocot-
rienol inhibited the TGF-b1-induced expres-
sion of a-SMA in a dose-dependent manner. 
Panel A shows a representative blot and panel 
B shows the results of densitometry analysis 
from seven cell lines. Data are expressed as 
mean value ± SD (n = 7). *P < 0.05 versus 
TGF-b1 (A and B). TGF-b1 enhanced a-SMA 
expression compared with control. g-Tocotrie-
nol inhibited the induction of a-SMA expres-
sion by TGF-b1. g-Tocotrienol alone did not 
affect a-SMA expression (C). Bar = 50 mM. 
α-SMA, α-smooth muscle actin; TGF, trans-
forming growth factor. 
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with 5% milk in TBS containing 0.05% Tween 20 for 1 
h at room temperature, blots were incubated with TBS-T 
containing the primary mouse monoclonal antibody for 
RhoA (1:1000; Santa Cruz Biotechnology) overnight at 
4 °C. The membranes were washed and incubated with 
horseradish peroxidase-conjugated anti-mouse IgG 
(1:10000) for 1 h at room temperature. Bands were vi-
sualized on an ImageQuant LAS 4000 mini with ECL 
reagents. 
Reagents
g-Tocotrienol was purchased from Cayman Chemical 
(Ann Arbor, MI). Y-27632 was purchased from Wako 
(Osaka, Japan). Simvastatin was purchased from Cal-
biochem (San Diego, CA).
Statistical Analyses
Data from individual assays are expressed as the mean 
± SD. Statistically significant differences were assessed 
by ANOVA (Bonferroni multiple comparisons test) or 
Student’s t-test with P-values < 0.05 considered signifi-
cant.
RESULTS
γ-Tocotrienol inhibits TGF-β1-induced expression 
of α-smooth muscle actin 
Western blotting and densitometry analysis showed 
that incubation of the ASM cells with TGF-b1 led to 
significant accumulation of a-SMA (Figs. 1A and 1B). 
Notably, co-treatment of cells with g-tocotrienol was 
sufficient to inhibit TGF-b1-induced a-SMA expres-
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fibronectin and collagen I protein (Figs. 2A and B). 
Induction of these extracellular matrix proteins was 
signifi cantly inhibited by g-tocotrienol (Figs. 2C and D), 
whereas g-tocotrienol alone had no signifi cant effect on 
the expression of fi bronectin or collagen I. 
Effects of γ-tocotrienol on TGF-β1-induced cell 
signaling 
As expected, TGF-b1 induced rapid and sustained phos-
phorylation of Smad2 and Smad3, which peaked 60-
120 min after treatment. However, in contrast to effects 
on TGF-β1-induced α-SMA, fi bronectin and collagen I, 
pretreatment with g-tocotrienol did not prevent 
TGF-b1-induced phosphorylation of Smad2 and 
Smad3 (Fig. 3A and 3B). 
γ-Tocotrienol inhibits TGF-β1-induced RhoA 
activation
We next examined the effects of pre-treatment of 
ASM cells with g-tocotrienol on RhoA activation 
in response to acute exposure to TGF-b1. No-
tably, TGF-b1-induced activation of RhoA was 
inhibited signifi cantly by g-tocotrienol (Fig. 4).  
γ-Tocotrienol does not change the TGF-β1-
induced increase of Id1 expression
We also examined the effects of TGF-b1 and 
g-tocotrienol on expression of the basic HLH 
transcription factor repressor Id1. After TGF-b1 
stimulation Id1 abundance increased markedly, 
peaking from 3 to 6 h later, then returning to near 
base-line levels after 12 hours. In the presence 
of g-tocotrienol, although TGF-β1 induced an in-
crease in Id1 from 1-3 hours, this was lower than 
seen with TGF-β1-alone, and returned to baseline 
within 6 hours of TGF-β1 exposure However, 
these changes were not statistically significant 
(Fig. 5).
Effect of the ROCK inhibitor on Id1 expres-
sion induced by TGF-β1
Finally, we examined the relationship between 
RhoA activation and Id1 expression. ASM cells 
were pretreated with Y27632 (10 mM) or simvas-
tatin (10 mM) for 1 h and then stimulated with 
TGF-b1 (2 ng/mL) for 3 h. While TGF-b1 signifi -
cantly increased Id1 expression, this increase was 
not inhibited by Y27632 or simvastatin (Fig. 6). 
DISCUSSION
In this study, we showed that g-tocotrienol inhib-
ited the TGF-b1-induced differentiation of human 
ASM cells into a contractile phenotype and the 
sion in a dose-dependent manner (P < 0.05) (Fig. 1B). 
In addition, immunocytochemical staining of the ASM 
showed that TGF-b1 markedly enhanced the density 
of a-smooth muscle actin (a-SMA) stress fibers, and 
though this accumulation was inhibited by g-tocotrienol, 
g-tocotrienol had no obvious impact on a-SMA fi bers in 
the absence of TGF-β1 (Fig. 1C).
γ-Tocotrienol inhibits TGF-β1-induced expression 
of ﬁ bronectin and collagen Ⅰ
TGF-b1 treatment greatly increased the abundance of 
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Fig. 2. g-Tocotrienol inhibits the TGF-b1-induced expression of fi bronec-
tin and collagen I. 
hTERT-ASM cells were pre-treated with g-tocotrienol for 1 h and then 
stimulated with TGF-b1 for 48 h. TGF-b1 increased the abundance of 
fi bronectin and collagen I (A and B). g-Tocotrienol signifi cantly attenuated 
the TGF-b1-induced expression of fi bronectin and collagen I (C and D). 
g-Tocotrienol alone did not affect the expression of fi bronectin and colla-
gen I (C and D). Data are expressed as mean ± SD (n = 8 for fi bronectin, 
n = 7 for collagen I). *P < 0.05 versus TGF-b1. TGF, transforming growth 
factor.
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Fig. 3. g-Tocotrienol does not inhibit TGF-b1-induced phosphorylation of Smad2 
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concomitant synthesis of collagen I and fi bronectin. Our 
results also revealed the signaling pathways that are af-
fected by g-tocotrienol in TGF-β1–exposed ASM cells, 
with a suppression of RhoA activation, but with no ef-
fects on Id1 expression or Smad phosphorylation. These 
fi ndings are important because ASM cell differentiation 
and synthesis of extracellular matrix protein contribute 
to the airway remodeling observed in asthma. Our data 
indicate that g-tocotrienol may prevent airway remod-
eling in asthma through inactivation of the RhoA/Rho 
kinase signaling pathway.
 In nature, four different isoforms of tocotrienol ex-
ist (a, b, g and d). From these, we selected g-tocotrienol 
since g-tocotrienol has shown to inhibit breast cancer 
cells proliferation and ASM cells proliferation and mi-
gration.21, 23 The effects of other isoforms on human 
ASM cells functions has not been investigated yet, oth-
er isoforms might have similar effects on human ASM 
cells and have benefi cial effects on airway remodeling 
of asthma. Further study is needed to evaluate the effect 
of a, b and d tocotrienol.  
 In this study, we used 10 to 50 mM of g-tocotrienol 
as in our previous study.21 We also confi rmed that the 
maximum concentration of g-tocotrienol (50 mM) had 
no cytotoxic effects on human ASM cells (data not 
shown). However, this concentration of g-tocotrienol ex-
hibits cytotoxic effect on other cell types.24, 25 Moreover, 
clinical application of g-tocotrienol by oral 
administration at this concentration might 
be diffi cult since serum level of tocotrienol 
was 0.54 ± 0.45 mM when hypercholesterol-
emia subjects received 250 mg/day of g-to-
cotrienol supplementation by oral adminis-
tration.26 Inhalation of g-tocotrienol might 
be one of the best delivery methods to reach 
effective concentration in the human lung. 
 Id1 is a member of the helix-loop-he-
lix proteins that act as negative regulators 
of DNA-binding of basic helix-loop-helix 
transcriptional factors.27 Id1 binds caveo-
lin-1 and induces epithelial-mesenchymal 
cell transition and migration of prostatic 
cancer cell lines.28 Furthermore, caveolin-1 
is required for expression of the contractile 
phenotype.29 Id1 is a critical mediator of 
TGF-b1-induced transdifferentiation in a 
rat hepatic stellate cell line.30 Furthermore, 
Je et al. reported that Id1 inhibits TGF-b1-
induced collagen expression in a dermal 
fi broblast cell line.31 Since Id1 is decreased 
by g-tocotrienol in breast cancer cell lines,17 
we considered that downregulation of Id1 
was involved in the mechanism underlying 
the g-tocotrienol inhibition of the fibrotic 
phenotype change of ASM cells. However, 
g-tocotrienol did not change the expression 
of Id1 in this study. Therefore, Id1 is not 
involved in this inhibitory effect of g-tocot-
rienol on the profi brotic changes induced by 
TGF-b1 in ASM cells. 
 We demonstrated that the TGF-b1-
induced activation of RhoA was prevented 
by g-tocotrienol. RhoA and its downstream 
Rho kinase play a key role in ASM cells 
contraction and airway hyperresponsive-
21
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Fig. 4. g-Tocotrienol inhibits TGF-b-induced acti-
vation of RhoA. 
A: Effect of g-tocotrienol on the activation of RhoA 
induced by TGF-b1 was studied. Rho activation 
peaked 5 min after TGF-b1 stimulation; this ef-
fect was inhibited by g-tocotrienol (10 to 50 mM). 
B: The activated RhoA bands were quantified by 
densitometry and expressed as a fold change rela-
tive to control unstimulated. The TGF-b1-induced 
activation of RhoA was inhibited significantly by 
g-tocotrienol. Data are expressed as mean ± SD (n 
= 5). *P < 0.05 versus TGF-b1. Rho, Ras homolog; 
TGF, transforming growth factor.
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Fig. 6. Simvastatin and the Rho-kinase inhibitor 
Y-27632 do not inhibit the TGF-b1-induced expression 
of Id1. 
hTERT-ASM cells were pretreated with Y27632 (10 
mM) or simvastatin (10 mM) for 1 h and then stimulated 
with TGF-b1 (2 ng/mL) for 3 h. TGF-b1 increased the 
expression of Id1, but this was not affected by either 
Y27632 or simvastatin. Data are expressed as mean ± 
SD (n = 4). Id, inhibitor of differentiation; TGF, trans-
forming growth factor.
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ness.32 In ASM cells, simvastatin suppresses the TGF-
b1-induced expression of collagen I and fibronectin.22 
Schaafsma et al. reported that PDGF induced RhoA 
activation and ASM cell contraction.33 We also report-
ed that g-tocotrienol inhibits the PDGF-BB-induced 
ASM cells proliferation and migration via inactivation 
of RhoA.21 These data suggest RhoA play a key role 
in ASM cells functions and g-tocotrienol might inhibit 
RhoA activation and as a result, inhibit airway remodel-
ing.
 Cheung et al. reported that Id1 induced epithelial 
cell invasion, which was regulated by Rho GTPases.34 In 
this study, we demonstrated that inhibition of the RhoA/
ROCK pathway by simvastatin or Y27632 did not affect 
the induction of Id1 by TGF-b1. Our results indicate that 
g-tocotrienol directly inhibits RhoA activation with-
out upregulating or downregulating Id1. However, the 
precise mechanism by which RhoA is inactivated by 
g-tocotrienol in the ASM remains unclear. Qureshi et al. 
reported that tocotrienols lower serum cholesterol,35, 36 
which is mediated by inhibition of HMG-CoA reductase 
by stimulating the ubiquitination and degradation of re-
ductase and by blocking sterol regulatory element-bind-
ing proteins.37 Future investigations will determine 
whether these pathways are involved in ASM cells. 
 We haven’t studied the role of reactive oxygen 
species (ROS) in this study. It has been reported that 
vitamin E has antioxidant activity and g-tocotrienol de-
creased PDGF-BB-induced ROS levels in human airway 
smooth muscle cells.21, 38 Since TGF-b1 generates ROS 
and ROS is related to airway remodeling in asthma and 
fibrosis in several organs,13, 39 reduction of ROS might be 
one of the inhibitory mechanisms of g-tocotrienol in this 
study. 
 The effect of current asthma therapies on airway 
remodeling in asthma has been investigated in several 
studies (reviewed in 40). Since the feature of ASM re-
modeling correlates with asthma severity,41 therapies 
targeting ASM are important. Bergeron et al. reported 
that inhaled corticosteroid (ICS) decrease a-smooth 
muscle area in peripheral airways. However, ICS did 
not decrease collagen III or a-smooth muscle area in the 
central airways nor did it affect the number of TGF-b 
positive cells in the submucosa.42 Chakir et al. also re-
ported that oral corticosteroid did not change TGF-b, 
collagen I and III levels in moderate to severe asthma.43 
Therefore, new drugs targeting the TGF-b1-induced 
profibrotic changes in airway mesenchymal cells are 
an unmet need. g-Tocotrienol exhibits anti-proliferative 
and inhibitory effects on migration of ASM cells. Fur-
thermore, we have demonstrated the anti-fibrotic effect 
of g-tocotrienol in TGF-b1 stimulated ASM cells. Thus, 
g-Tocotrienol might be possible therapeutic option tar-
geting airway remodeling in asthma. 
 In conclusion, we demonstrated the effect of g-to-
cotrienol on the TGF-b1-induced differentiation of 
human ASM cells and extracellular matrix deposition. 
We also defined the key elements of the downstream 
signaling cascade inhibited by g-tocotrienol in the ASM 
cells activated by TGF-b1. These new findings suggest 
that g-tocotrienol could become a therapeutic agent to 
regulate airway remodeling in asthma.
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